$DORM
Dorman Products, Inc.

2024 Q3 Form 10-Q Financial Statement

#000086878024000033 Filed on August 02, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $503.8M $503.0M
YoY Change 4.83% 7.76%
Cost Of Revenue $300.0M $303.6M
YoY Change -5.39% -5.81%
Gross Profit $203.8M $199.4M
YoY Change 24.65% 38.02%
Gross Profit Margin 40.46% 39.65%
Selling, General & Admin $124.5M $126.9M
YoY Change 14.98% 0.46%
% of Gross Profit 61.1% 63.67%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $14.81M $14.35M
YoY Change 10.3% 6.0%
% of Gross Profit 7.27% 7.2%
Operating Expenses $124.5M $126.9M
YoY Change 14.98% 0.46%
Operating Profit $79.27M $72.45M
YoY Change 43.61% 299.98%
Interest Expense -$9.762M -$10.20M
YoY Change -22.31% -185.35%
% of Operating Profit -12.31% -14.08%
Other Income/Expense, Net $1.615M $136.0K
YoY Change 307.83% -61.9%
Pretax Income $71.12M $62.39M
YoY Change 65.29% 857.13%
Income Tax $15.87M $14.98M
% Of Pretax Income 22.31% 24.01%
Net Earnings $55.25M $47.41M
YoY Change 68.61% 734.24%
Net Earnings / Revenue 10.97% 9.43%
Basic Earnings Per Share $1.81 $1.53
Diluted Earnings Per Share $1.80 $1.53
COMMON SHARES
Basic Shares Outstanding 30.57M shares 31.01M shares
Diluted Shares Outstanding 30.74M shares 31.07M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.13M $47.47M
YoY Change 26.53% 42.51%
Cash & Equivalents $45.13M $47.47M
Short-Term Investments
Other Short-Term Assets $34.66M $39.01M
YoY Change -40.02% -2.89%
Inventory $665.2M $620.4M
Prepaid Expenses
Receivables $571.1M $526.2M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.316B $1.233B
YoY Change 10.71% 3.64%
LONG-TERM ASSETS
Property, Plant & Equipment $165.7M $165.8M
YoY Change -36.46% 9.39%
Goodwill $443.3M $443.0M
YoY Change -0.12% -0.07%
Intangibles $284.1M $290.3M
YoY Change -9.09% -8.43%
Long-Term Investments
YoY Change
Other Assets $47.63M $51.16M
YoY Change -6.2% 1.31%
Total Long-Term Assets $1.048B $1.053B
YoY Change -1.88% -1.7%
TOTAL ASSETS
Total Short-Term Assets $1.316B $1.233B
Total Long-Term Assets $1.048B $1.053B
Total Assets $2.364B $2.286B
YoY Change 4.75% 1.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $205.9M $164.7M
YoY Change 35.36% 13.02%
Accrued Expenses $274.9M $264.4M
YoY Change 14.93% 13.33%
Deferred Revenue
YoY Change
Short-Term Debt $61.76M $69.46M
YoY Change -62.92% -67.76%
Long-Term Debt Due $18.75M $15.63M
YoY Change 50.0% 25.0%
Total Short-Term Liabilities $561.3M $514.1M
YoY Change -1.59% -15.29%
LONG-TERM LIABILITIES
Long-Term Debt $455.0M $461.2M
YoY Change -4.49% -3.81%
Other Long-Term Liabilities $9.203M $10.17M
YoY Change -91.57% -39.31%
Total Long-Term Liabilities $464.2M $471.4M
YoY Change -20.71% -5.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $561.3M $514.1M
Total Long-Term Liabilities $464.2M $471.4M
Total Liabilities $1.026B $985.5M
YoY Change -12.4% -10.66%
SHAREHOLDERS EQUITY
Retained Earnings $1.127B $1.099B
YoY Change 13.42% 14.24%
Common Stock $110.9M $107.0M
YoY Change 17.02% 17.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.235B $1.201B
YoY Change
Total Liabilities & Shareholders Equity $2.364B $2.286B
YoY Change 4.75% 1.11%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $55.25M $47.41M
YoY Change 68.61% 734.24%
Depreciation, Depletion And Amortization $14.81M $14.35M
YoY Change 10.3% 6.0%
Cash From Operating Activities $44.29M $63.35M
YoY Change -33.57% 141.7%
INVESTING ACTIVITIES
Capital Expenditures $8.555M $11.94M
YoY Change -32.81% 13.27%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$8.555M -$11.94M
YoY Change -33.85% 16.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -38.11M -38.36M
YoY Change -25.91% 33.83%
NET CHANGE
Cash From Operating Activities 44.29M 63.35M
Cash From Investing Activities -8.555M -11.94M
Cash From Financing Activities -38.11M -38.36M
Net Change In Cash -2.367M 13.05M
YoY Change -202.2% -202.56%
FREE CASH FLOW
Cash From Operating Activities $44.29M $63.35M
Capital Expenditures $8.555M $11.94M
Free Cash Flow $35.74M $51.41M
YoY Change -33.75% 228.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
961000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-91000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-519000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
47410000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1201320000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1049144000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
81000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3123000 usd
CY2023Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
395000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1004000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-221000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
566000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
32770000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1086072000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1168203000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
559000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6780000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
52140000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
961000 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-1663000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1618000 usd
us-gaap Net Income Loss
NetIncomeLoss
80238000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1201320000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1042631000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1130000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5435000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
828000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1004000 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-2438000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
685000 usd
us-gaap Net Income Loss
NetIncomeLoss
38453000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1086072000 usd
us-gaap Profit Loss
ProfitLoss
80238000 usd
us-gaap Profit Loss
ProfitLoss
38453000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
28203000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
26969000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-12400000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-15000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2357000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
472000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2980000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6780000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5435000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-627000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
27522000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-16745000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-113331000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5739000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12229000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3339000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3526000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-12112000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-28028000 usd
dorm Increase Decrease In Accrued Customer Rebates And Returns
IncreaseDecreaseInAccruedCustomerRebatesAndReturns
-806000 usd
dorm Increase Decrease In Accrued Customer Rebates And Returns
IncreaseDecreaseInAccruedCustomerRebatesAndReturns
-2713000 usd
dorm Increase Decrease In Accrued Compensation And Other Liabilities
IncreaseDecreaseInAccruedCompensationAndOtherLiabilities
4275000 usd
dorm Increase Decrease In Accrued Compensation And Other Liabilities
IncreaseDecreaseInAccruedCompensationAndOtherLiabilities
-10221000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
115329000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
92886000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-67000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22690000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23269000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22690000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23202000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
23300000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
72800000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6250000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6250000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
200000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
559000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1130000 usd
dorm Purchase And Cancellation Of Common Stock
PurchaseAndCancellationOfCommonStock
52033000 usd
dorm Purchase And Cancellation Of Common Stock
PurchaseAndCancellationOfCommonStock
828000 usd
dorm Proceeds Payments From Other Stock Related Activity
ProceedsPaymentsFromOtherStockRelatedActivity
-704000 usd
dorm Proceeds Payments From Other Stock Related Activity
ProceedsPaymentsFromOtherStockRelatedActivity
-1343000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-81928000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-80091000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-58000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10653000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10368000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36814000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46034000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47467000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35666000 usd
us-gaap Interest Paid Net
InterestPaidNet
20332000 usd
us-gaap Interest Paid Net
InterestPaidNet
26745000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
26374000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14779000 usd
CY2024Q2 us-gaap Proceeds From Sale Of Finance Receivables
ProceedsFromSaleOfFinanceReceivables
251538000 usd
CY2023Q3 us-gaap Proceeds From Sale Of Finance Receivables
ProceedsFromSaleOfFinanceReceivables
241937000 usd
us-gaap Proceeds From Sale Of Finance Receivables
ProceedsFromSaleOfFinanceReceivables
536756000 usd
us-gaap Proceeds From Sale Of Finance Receivables
ProceedsFromSaleOfFinanceReceivables
479677000 usd
CY2024Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
29614000 usd
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
29750000 usd
CY2024Q2 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
192151000 usd
CY2023Q4 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
211805000 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
389412000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
387668000 usd
CY2024Q2 us-gaap Inventory Supplies Net Of Reserves
InventorySuppliesNetOfReserves
9194000 usd
CY2023Q4 us-gaap Inventory Supplies Net Of Reserves
InventorySuppliesNetOfReserves
8152000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
620371000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
637375000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
443889000 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-869000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
443020000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
355317000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
65040000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
290277000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
355317000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
53761000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
301556000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5500000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5500000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11100000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11000000.0 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
62386000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
43029000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
106179000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
49547000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
502951000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
480568000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
971652000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
947306000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High
BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
102000000.0 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
257554 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
97.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
184007 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
98.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
55401 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
88.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
27523 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
112.99
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
358637 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
98.30
CY2024Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
400000 usd
CY2023Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
600000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
800000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1000000.0 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
311217 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
86.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
6416 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
94.50
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10311 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
63.73
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
294490 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
87.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2192000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
192637 shares
CY2024Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
83.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y3M18D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2160000 usd
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
13555 shares
CY2024Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
13555 shares
CY2023Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
14975 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
14975 shares
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
225000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
353000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
272000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
295000 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
47410000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
32770000 usd
us-gaap Net Income Loss
NetIncomeLoss
80238000 usd
us-gaap Net Income Loss
NetIncomeLoss
38453000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30957000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31466000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31048000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31451000 shares
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
114000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
62000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
112000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
82000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31071000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31528000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31160000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31533000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.22
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.22
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4700000 usd
CY2024Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4400000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000868780-24-000033-index-headers.html Edgar Link pending
0000868780-24-000033-index.html Edgar Link pending
0000868780-24-000033.txt Edgar Link pending
0000868780-24-000033-xbrl.zip Edgar Link pending
dorm-20240629.htm Edgar Link pending
dorm-20240629.xsd Edgar Link pending
dorm-20240629x10qexx311.htm Edgar Link pending
dorm-20240629x10qexx312.htm Edgar Link pending
dorm-20240629x10qexx32.htm Edgar Link pending
dorm-20240629_g1.jpg Edgar Link pending
exhibit101.htm Edgar Link pending
exhibit101001.jpg Edgar Link pending
exhibit101002.jpg Edgar Link pending
exhibit101003.jpg Edgar Link pending
exhibit101004.jpg Edgar Link pending
exhibit101005.jpg Edgar Link pending
exhibit101006.jpg Edgar Link pending
exhibit101007.jpg Edgar Link pending
exhibit101008.jpg Edgar Link pending
exhibit101009.jpg Edgar Link pending
exhibit101010.jpg Edgar Link pending
exhibit101011.jpg Edgar Link pending
exhibit101012.jpg Edgar Link pending
exhibit101013.jpg Edgar Link pending
exhibit101014.jpg Edgar Link pending
exhibit101015.jpg Edgar Link pending
exhibit101016.jpg Edgar Link pending
exhibit101017.jpg Edgar Link pending
exhibit101018.jpg Edgar Link pending
exhibit101019.jpg Edgar Link pending
exhibit101020.jpg Edgar Link pending
exhibit101021.jpg Edgar Link pending
exhibit101022.jpg Edgar Link pending
exhibit101023.jpg Edgar Link pending
dorm-20240629_def.xml Edgar Link unprocessable
dorm-20240629_htm.xml Edgar Link completed
dorm-20240629_lab.xml Edgar Link unprocessable
dorm-20240629_pre.xml Edgar Link unprocessable
exhibit101024.jpg Edgar Link pending
exhibit101025.jpg Edgar Link pending
exhibit101026.jpg Edgar Link pending
exhibit101027.jpg Edgar Link pending
exhibit101028.jpg Edgar Link pending
exhibit101029.jpg Edgar Link pending
exhibit101030.jpg Edgar Link pending
exhibit101031.jpg Edgar Link pending
exhibit101032.jpg Edgar Link pending
exhibit101033.jpg Edgar Link pending
exhibit101034.jpg Edgar Link pending
exhibit101035.jpg Edgar Link pending
exhibit101036.jpg Edgar Link pending
exhibit101037.jpg Edgar Link pending
exhibit101038.jpg Edgar Link pending
exhibit101039.jpg Edgar Link pending
exhibit101040.jpg Edgar Link pending
exhibit101041.jpg Edgar Link pending
exhibit101042.jpg Edgar Link pending
exhibit101043.jpg Edgar Link pending
exhibit101044.jpg Edgar Link pending
exhibit101045.jpg Edgar Link pending
exhibit101046.jpg Edgar Link pending
exhibit101047.jpg Edgar Link pending
exhibit101048.jpg Edgar Link pending
exhibit101049.jpg Edgar Link pending
exhibit101050.jpg Edgar Link pending
exhibit101051.jpg Edgar Link pending
exhibit101052.jpg Edgar Link pending
exhibit101053.jpg Edgar Link pending
exhibit101054.jpg Edgar Link pending
exhibit101055.jpg Edgar Link pending
exhibit101056.jpg Edgar Link pending
exhibit101057.jpg Edgar Link pending
exhibit101058.jpg Edgar Link pending
exhibit101059.jpg Edgar Link pending
exhibit101060.jpg Edgar Link pending
exhibit101061.jpg Edgar Link pending
exhibit101062.jpg Edgar Link pending
exhibit101063.jpg Edgar Link pending
exhibit101064.jpg Edgar Link pending
exhibit101065.jpg Edgar Link pending
exhibit101066.jpg Edgar Link pending
exhibit101067.jpg Edgar Link pending
exhibit101068.jpg Edgar Link pending
exhibit101069.jpg Edgar Link pending
exhibit101070.jpg Edgar Link pending
exhibit101071.jpg Edgar Link pending
exhibit101072.jpg Edgar Link pending
exhibit101073.jpg Edgar Link pending
exhibit101074.jpg Edgar Link pending
exhibit101075.jpg Edgar Link pending
exhibit101076.jpg Edgar Link pending
exhibit101077.jpg Edgar Link pending
exhibit101078.jpg Edgar Link pending
exhibit101079.jpg Edgar Link pending
exhibit101080.jpg Edgar Link pending
exhibit101081.jpg Edgar Link pending
exhibit101082.jpg Edgar Link pending
exhibit101083.jpg Edgar Link pending
exhibit101084.jpg Edgar Link pending
exhibit101085.jpg Edgar Link pending
exhibit101086.jpg Edgar Link pending
exhibit101087.jpg Edgar Link pending
exhibit101088.jpg Edgar Link pending
exhibit101089.jpg Edgar Link pending
exhibit101090.jpg Edgar Link pending
exhibit101091.jpg Edgar Link pending
exhibit101092.jpg Edgar Link pending
exhibit101093.jpg Edgar Link pending
exhibit101094.jpg Edgar Link pending
exhibit101095.jpg Edgar Link pending
exhibit101096.jpg Edgar Link pending
exhibit101097.jpg Edgar Link pending
exhibit101098.jpg Edgar Link pending
exhibit101099.jpg Edgar Link pending
exhibit101100.jpg Edgar Link pending
exhibit101101.jpg Edgar Link pending
exhibit101102.jpg Edgar Link pending
exhibit101103.jpg Edgar Link pending
exhibit101104.jpg Edgar Link pending
exhibit101105.jpg Edgar Link pending
exhibit101106.jpg Edgar Link pending
exhibit101107.jpg Edgar Link pending
exhibit101108.jpg Edgar Link pending
exhibit101109.jpg Edgar Link pending
exhibit101110.jpg Edgar Link pending
exhibit101111.jpg Edgar Link pending
exhibit101112.jpg Edgar Link pending
exhibit101113.jpg Edgar Link pending
exhibit101114.jpg Edgar Link pending
exhibit101115.jpg Edgar Link pending
exhibit101116.jpg Edgar Link pending
exhibit101117.jpg Edgar Link pending
exhibit101118.jpg Edgar Link pending
exhibit101119.jpg Edgar Link pending
exhibit101120.jpg Edgar Link pending
exhibit101121.jpg Edgar Link pending
exhibit101122.jpg Edgar Link pending
exhibit101123.jpg Edgar Link pending
exhibit101124.jpg Edgar Link pending
exhibit101125.jpg Edgar Link pending
exhibit101126.jpg Edgar Link pending
exhibit101127.jpg Edgar Link pending
exhibit101128.jpg Edgar Link pending
exhibit101129.jpg Edgar Link pending
exhibit101130.jpg Edgar Link pending
exhibit101131.jpg Edgar Link pending
exhibit101132.jpg Edgar Link pending
exhibit101133.jpg Edgar Link pending
exhibit101134.jpg Edgar Link pending
exhibit101135.jpg Edgar Link pending
exhibit101136.jpg Edgar Link pending
exhibit101137.jpg Edgar Link pending
exhibit101138.jpg Edgar Link pending
exhibit101139.jpg Edgar Link pending
exhibit101140.jpg Edgar Link pending
exhibit101141.jpg Edgar Link pending
exhibit101142.jpg Edgar Link pending
exhibit101143.jpg Edgar Link pending
exhibit101144.jpg Edgar Link pending
exhibit101145.jpg Edgar Link pending
exhibit101146.jpg Edgar Link pending
exhibit101147.jpg Edgar Link pending
exhibit101148.jpg Edgar Link pending
exhibit101149.jpg Edgar Link pending
exhibit101150.jpg Edgar Link pending
exhibit101151.jpg Edgar Link pending
exhibit101152.jpg Edgar Link pending
exhibit101153.jpg Edgar Link pending
exhibit101154.jpg Edgar Link pending
exhibit101155.jpg Edgar Link pending
exhibit101156.jpg Edgar Link pending
exhibit101157.jpg Edgar Link pending
exhibit101158.jpg Edgar Link pending
exhibit101159.jpg Edgar Link pending
exhibit101160.jpg Edgar Link pending
exhibit101161.jpg Edgar Link pending
exhibit101162.jpg Edgar Link pending
exhibit101163.jpg Edgar Link pending
exhibit101164.jpg Edgar Link pending
exhibit101165.jpg Edgar Link pending
exhibit101166.jpg Edgar Link pending
exhibit101167.jpg Edgar Link pending
exhibit101168.jpg Edgar Link pending
exhibit101169.jpg Edgar Link pending
exhibit101170.jpg Edgar Link pending
exhibit101171.jpg Edgar Link pending
exhibit101172.jpg Edgar Link pending
exhibit101173.jpg Edgar Link pending
exhibit101174.jpg Edgar Link pending
exhibit101175.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dorm-20240629_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable